Literature DB >> 23897319

Renal cancer in von Hippel-Lindau disease and related syndromes.

Birke Bausch1, Cordula Jilg, Sven Gläsker, Alexander Vortmeyer, Niklas Lützen, Alexandra Anton, Charis Eng, Hartmut P H Neumann.   

Abstract

Sporadic and hereditary forms of renal cell carcinoma (RCC), von Hippel-Lindau (VHL) disease and the familial paraganglioma syndromes are closely related in terms of their clinical, molecular, and genetic aspects. Most RCCs occur sporadically and the heritable fraction of RCC is estimated to be just 2-4%. An understanding of the molecular genetic basis, the disease-specific and gene-specific biology and the clinical characteristics of these cancer syndromes is of utmost importance for effective genetic diagnosis and appropriate treatment. In addition, such insight will improve our understanding of sporadic RCCs. To date, 10 different heritable RCC syndromes have been described. VHL syndrome is the oldest known hereditary RCC syndrome. Similar to VHL disease, phaeochromocytoma is a major manifestation of the paraganglioma syndromes types 1, 3 and 4 in which RCCs have been reported. These syndromes are therefore regarded as VHL-related disorders and are included in this Review. Multifocal tumours, bilateral occurrence, a young age at diagnosis and/or family history are clinical red flags suggestive of hereditary disease and should trigger referral for genetic and molecular analysis. The identification of an underlying genetic alteration enables gene-specific risk assessment and opens up the possibility of a tailored follow-up strategy and specific surveillance protocols as the basis of effective preventive medicine. The important goals of preventive medicine are to increase the life expectancy of affected patients and to improve their quality of life. The study of seemingly rare hereditary syndromes and their susceptibility genes has consistently revealed clues regarding the aetiology and pathogenesis of these diseases, and can aid diagnosis and the development of therapeutics for patients affected by much more common sporadic counterparts.

Entities:  

Mesh:

Year:  2013        PMID: 23897319     DOI: 10.1038/nrneph.2013.144

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  85 in total

1.  Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma.

Authors:  Birke Bausch; Wiktor Borozdin; Hartmut P H Neumann
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

2.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

3.  Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data.

Authors:  Eirikur Guðmundsson; Henrik Hellborg; Sven Lundstam; Stina Erikson; Börje Ljungberg
Journal:  Eur Urol       Date:  2011-07-01       Impact factor: 20.096

4.  Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma.

Authors:  C A Jilg; H P Neumann; S Gläsker; O Schäfer; P U Ardelt; M Schwardt; W Schultze-Seemann
Journal:  Urol Int       Date:  2011-12-09       Impact factor: 2.089

5.  Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.

Authors:  Sakari Vanharanta; Mary Buchta; Sarah R McWhinney; Sanna K Virta; Mariola Peçzkowska; Carl D Morrison; Rainer Lehtonen; Andrzej Januszewicz; Heikki Järvinen; Matti Juhola; Jukka-Pekka Mecklin; Eero Pukkala; Riitta Herva; Maija Kiuru; Nina N Nupponen; Lauri A Aaltonen; Hartmut P H Neumann; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

Review 6.  Molecular basis of the VHL hereditary cancer syndrome.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

7.  Patterns of intervention for renal lesions in von Hippel-Lindau disease.

Authors:  Surena F Matin; Kamran Ahrar; Christopher G Wood; Molly Daniels; Eric Jonasch
Journal:  BJU Int       Date:  2008-05-15       Impact factor: 5.588

Review 8.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

9.  Sunitinib efficacy against advanced renal cell carcinoma.

Authors:  Robert J Motzer; M Dror Michaelson; Jonathan Rosenberg; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; George Wilding
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450

10.  Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.

Authors:  Christopher J Ricketts; Brian Shuch; Cathy D Vocke; Adam R Metwalli; Gennady Bratslavsky; Lindsay Middelton; Youfeng Yang; Ming-Hui Wei; Stephen E Pautler; James Peterson; Catherine A Stolle; Berton Zbar; Maria J Merino; Laura S Schmidt; Peter A Pinto; Ramaprasad Srinivasan; Karel Pacak; W Marston Linehan
Journal:  J Urol       Date:  2012-10-18       Impact factor: 7.450

View more
  22 in total

Review 1.  An approach to cystic kidney diseases: the clinician's view.

Authors:  Christine E Kurschat; Roman-Ulrich Müller; Mareike Franke; David Maintz; Bernhard Schermer; Thomas Benzing
Journal:  Nat Rev Nephrol       Date:  2014-09-30       Impact factor: 28.314

Review 2.  The emerging role of extracellular vesicles as biomarkers for urogenital cancers.

Authors:  Muhammad Nawaz; Giovanni Camussi; Hadi Valadi; Irina Nazarenko; Karin Ekström; Xiaoqin Wang; Simona Principe; Neelam Shah; Naeem M Ashraf; Farah Fatima; Luciano Neder; Thomas Kislinger
Journal:  Nat Rev Urol       Date:  2014-11-18       Impact factor: 14.432

Review 3.  Metabolic reprogramming in clear cell renal cell carcinoma.

Authors:  Hiromi I Wettersten; Omran Abu Aboud; Primo N Lara; Robert H Weiss
Journal:  Nat Rev Nephrol       Date:  2017-05-08       Impact factor: 28.314

4.  Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review.

Authors:  Kyung Hwa Choi; Young Dong Yu; Moon Hyung Kang; Dong Soo Park
Journal:  Can Urol Assoc J       Date:  2015-09-09       Impact factor: 1.862

5.  Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association.

Authors:  Karen Gomez Hernandez; Shereen Ezzat; Chantal F Morel; Carol Swallow; Mirek Otremba; Brendan C Dickson; Sylvia L Asa; Ozgur Mete
Journal:  Virchows Arch       Date:  2015-03-24       Impact factor: 4.064

Review 6.  Renal cell carcinoma in young patients: a review of recent literature.

Authors:  Michael Daugherty; Gennady Bratslavsky
Journal:  Curr Urol Rep       Date:  2015-02       Impact factor: 3.092

Review 7.  [Hereditary renal tumors: More common than expected?].

Authors:  A Agaimy; A Hartmann
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

8.  β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma.

Authors:  Ruhee Dere; Ashley Lyn Perkins; Tasneem Bawa-Khalfe; Darius Jonasch; Cheryl Lyn Walker
Journal:  J Am Soc Nephrol       Date:  2014-10-13       Impact factor: 10.121

Review 9.  Von Hippel-Lindau disease.

Authors:  Prashant Chittiboina; Russell R Lonser
Journal:  Handb Clin Neurol       Date:  2015

Review 10.  Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology.

Authors:  Tianying Xing; Huiying He
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.